Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.10, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

Fintel reports that on January 28, 2026, Barclays upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.18% Upside As of ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.

The biotech could be on the verge of expanding its lineup and entering a new era of growth.

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

FILSPARI drives IgAN growth, but FSGS approval could unlock a $2 billion market amid rising competition. Read here for more.

In the latest close session, ON Semiconductor Corp. (ON) was down 3.71% at $59.89. The stock's change was less than the S&P 500's daily loss of 0.43%. Meanwhile, the Dow experienced a drop of 0.37%, ...